ArticleGut2002
High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6.
Article in Gut, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 124 citations in OpenAlex.
- Bidirectional causal links between diabetes mellitus and autoimmune liver diseases: Insights from Mendelian randomization.Journal of diabetes investigation · 2025Article
- Oral N-acetylcysteine ameliorates liver fibrosis and enhances regenerative responses in Mdr2 knockout mice.Scientific reports · 2024Article
- Anti-integrin αvβ6 autoantibodies in patients with primary sclerosing cholangitis.Journal of gastroenterology · 2023Article
- Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Review.Journal of clinical and translational hepatology · 2022Review
- Review
- The Role of Gut Microbiota in Some Liver Diseases: From an Immunological Perspective.Frontiers in immunology · 2022Review
- Environmental exposure as a risk-modifying factor in liver diseases: Knowns and unknowns.Acta pharmaceutica Sinica. B · 2021Review
- The two facets of gp130 signalling in liver tumorigenesis.Seminars in immunopathology · 2021Review
- Antigen presentation, autoantibody production, and therapeutic targets in autoimmune liver disease.Cellular & molecular immunology · 2021Review
- The Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases.Frontiers in immunology · 2021Review
- The search for the Holy Grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia.Auto- immunity highlights · 2020Review
- Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?Diseases (Basel, Switzerland) · 2019Review
- Abnormal Expression of ERα in Cholangiocytes of Patients With Primary Biliary Cholangitis Mediated Intrahepatic Bile Duct Inflammation.Frontiers in immunology · 2019Article
- Rituximab Induction to Prevent the Recurrence of PSC After Liver Transplantation-The Lessons Learned From ABO-Incompatible Living Donor Liver Transplantation.Transplantation direct · 2018Article
- Autoantibodies in Autoimmune Liver Disease-Clinical and Diagnostic Relevance.Frontiers in immunology · 2018Review
- The Role of Genetic and Immune Factors for the Pathogenesis of Primary Sclerosing Cholangitis in Childhood.Gastroenterology research and practice · 2016Review
- Biliary Mucosal Barrier and Microbiome.Viszeralmedizin · 2015Review
- Mechanisms of tissue injury in autoimmune liver diseases.Seminars in immunopathology · 2014Review
- Re-examination of sinusoidal deposition of complement 4d in liver allografts: experience from a single institution.International journal of clinical and experimental pathology · 2014Article
- Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.Gastroenterology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimSera of patients with autoimmune liver diseases were investigated for the presence of autoantibodies binding to human biliary epithelial cells (BECs). Furthermore, their functional capacity was investigated by testing their capacity to fix complement as well as induce expression of various adhesion molecules and production of cytokines.
methodsSera from patients with various stages of primary sclerosing cholangitis (PSC; n=30), primary biliary cirrhosis (PBC; n=29), autoimmune hepatitis (AIH; n=25), and normal controls (n=12) were investigated for the presence of antibodies that reacted with unstimulated and cytokine stimulated BECs isolated from a normal healthy liver. To demonstrate organ specificity, lung epithelial cells (LECs) were used as control cells. Antibodies were tested for their functional capacity.
resultsCompared with controls (8%), significantly higher numbers of PSC patients (63%, p=0.001), but not PBC (37%, NS) or AIH (16%, NS) patients, had anti-BEC antibodies. In 90% of PSC patients, the autoantibodies reacted only with cytokine stimulated target cells. Lower numbers of PSC (6%), PBC (10%), and AIH (0%) patients had LEC antibodies. Other significant findings were that anti-BEC antibodies were found in (i) PSC patients with either the HLA-DRB1*0301 or DR2 allele compared with those without (p=0.007); and (ii) in PBC patients with end stage disease compared with those without (p=0.018). Furthermore, anti-BEC antibodies from PSC and PBC but not AIH patients induced BECs to produce high levels of the cytokine interleukin 6. IgM and IgG fractions isolated from PSC but not PBC and AIH sera induced significantly increased expression of the cell adhesion molecule CD44. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis and western blot analysis of BEC membranes demonstrated a specific band of 40 kDa with PSC sera and 45, 42, 30, and 33 kDa bands with PBC sera, which were absent in control groups.
conclusionThus for the first time we have demonstrated the presence of functionally important autoantibodies to cell surface expressed antigens on the relevant target cells of destruction, namely BECs, in PSC and PBC. These finding have important implications for the pathogenesis of bile duct destruction in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.